At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
GW823093 15mg +2 moredrug
Likely dose
GW823093 15mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PK/PD Study of GW823093 in Japanese Subjects With T2DM: A Single-blind, Placebo Controlled, Randomized, Multi-dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GW823093C Administered Orally for 7 Days in Japanese Subjects With Type 2 Diabetes
In Brief
A Phase 2 clinical trial evaluating GW823093 15mg, GW823093 placebo capsule, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 30 participants across 1 site.
Detailed Summary
To investigate the preliminary pharmacokinetics, pharmacodynamics, safety and tolerability of GW823093 at doses of 15mg and 30mg given once daily for 7 days in Japanese Type 2 diabetes mellitus (T2DM) patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2006
Primary CompletionJun 2006
First PostedSep 2006
TodayJul 2026
First PostedSep 7, 2006
Enrollment StartMar 22, 2006
Primary CompletionJun 28, 2006
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 19.8 years ago
Interventions
GW823093 15mgdrug
White opaque capsule containing 15mg of GW823093 as free base
GW823093 placebo capsuledrug
Matching placebo of GW823093 capsule or 15mg capsule
GW823093 30mgdrug
White opaque capsule containing 15mg of GW823093 as free base